Needham Reiterates Hold on ResMed
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Hold rating on ResMed (NYSE:RMD).
October 01, 2024 | 9:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Mike Matson has reiterated a Hold rating on ResMed, indicating a neutral stance on the stock.
The reiteration of a Hold rating by Needham suggests that the analyst does not see significant upside or downside in the short term for ResMed. This neutral stance implies that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100